Table 2.
Investment in respiratory infectious disease system or theme by the sum and number of studies
| Disease | Number of studies | Percentage of respiratory study number | Total funding | Percentage of respiratory funding | Mean award, £ (SD) | Median award, £ (IQR) | Top funder, millions (%) |
|---|---|---|---|---|---|---|---|
| Respiratory | 1010 | N/a | £378 975 715 | N/a | 375 224 (703 285) | 169 536 (48 568–366 068) | Wellcome, 126.9 (33.5) |
| Global health | 108 | 10.7 | £64 586 190 | 17.0 | 598 020 (1 124 776) | 203 098 (32 694–634 223) | Wellcome, 31.6 (49.0) |
| Vaccinology | 102 | 10.1 | £51 990 973 | 13.7 | 509 715 (743 113) | 224 743 (86 947–578 651) | Wellcome, 18.4 (35.5) |
| Therapeutics | 84 | 8.3 | £39 252 141 | 10.4 | 467 287 (1 164 335) | 171 012 (33 002–375 749) | Wellcome, 14.2 (36.3) |
| HIV-associated research | 72 | 7.1 | £30 364 829 | 8.0 | 421 733 (850 472) | 150 840 (31 005–401 660) | Wellcome, 15.1 (49.8) |
| Paediatrics | 76 | 7.5 | £21 687 716 | 5.7 | 285 364 (546 195) | 117 482 (36 266–331 369) | Wellcome, 10.7 (42.1) |
| Diagnostics | 54 | 5.3 | £17 981 636 | 4.7 | 332 993 (574 074) | 93 961 (35 007–363 525) | European Commission, 6.0 (32.1) |
| Antimicrobial resistance | 43 | 4.3 | £14 514 444 | 3.8 | 337 545 (851 395) | 152 436 (59 328–325 187) | Wellcome, 4.1 (28.1) |
| Primary care | 49 | 4.9 | £10 201 844 | 2.7 | 208 201 (368 848) | 75 118 (20 568–185 131) | Wellcome, 3.0 (29.9) |
| Economics | 9 | 0.9 | £1 681 487 | 0.4 | 186 832 (238 625) | 172 976 (34 182–184 195) | Department of Health, 1.3 (75.7) |
N/a, not applicable.